Connect with us

Health Broadcasting Service

Sanofi’s Dupixent gets U.S. approval to treat eczema in young children

HBS Reporting

Sanofi’s Dupixent gets U.S. approval to treat eczema in young children

Sanofi’s Dupixent gets U.S. approval to treat eczema in young children

June 7 (Reuters) – The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA) and Regeneron Pharmaceuticals Inc’s (REGN.O) anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi and Regeneron said.Sanofi records global net product sales of Dupixent, while Regeneron gets a share of profit or loss from the drug.The approval for the drug in children aged 6 months to 5 years was based on data from a late-stage study in which Dupixent improved skin clearance and reduced severity of eczema when used with a corticosteroids cream.The drug works by blocking the inflammation-causing IL-4 and IL-13 proteins involved in the body’s immune response that the companies believe to be underlying reasons for a number of inflammatory conditions.Dupixent, with 2021 sales of 5.25 billion euros, accounted for 13.9% of Sanofi’s revenue, making it the Paris-listed company’s best-selling product.Dupixent is already approved for treating a range of diseases in adult populations in the United States, including eczema or atopic dermatitis, severe asthma and an allergic inflammation of the esophagus.Atopic dermatitis, or eczema, is a chronic skin condition that causes inflammation and irritation of skin. It affects about 30% of the U.S. population, mostly children and adolescents, according to the National Institute of Allergy and Infectious Diseases.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published.

More in HBS Reporting